GLP1R and obesity disorder: Recent approvals by the Brazilian Health Regulatory Agency (Anvisa, acronym inPortuguese) of treatment drugs that simulate the actions of the GLP-1 peptide in thebody (liraglutide and semaglutide) for weight loss in adolescents (12 years of age andolder) brings questions about the relevance and risks of using these drugs to treatchildhood obesity.